Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

Daniel Catovsky(Leuka), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), A J Smith(Southampton General Hospital), Zadie Davis(Royal Bournemouth Hospital), R. F. Bezares(Hospital General de Agudos Dr. TEODORO ALVAREZ), Estella Matutes(Institute of Cancer Research), William Hamilton(University of Exeter), Monica Else(Institute of Cancer Research), AG Bosanquet, Rachel Wade(Northumbria Healthcare NHS Foundation Trust), A R Pettitt(University of Liverpool)
The Lancet
July 1, 2007
10.1016/s0140-6736(07)61125-8
Cited by 679

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k